jNeuroKids l

l .tJM

Table of contents NeuroKids r'6

A Emergency and intensive careA.01 Febrile seizures

A.02 Status epiLepticus (SE)A.03 Acute dystonic reactionA.04 Acute Ataxia

A.05 Acute increased intracraniaL

pressure (ICP)A.06 Guillain-Barre Syndrome (GBS)A.07 Neurometabolic dysfunctionA.08 Traumatic brain injury (TBI)A.09 Paediatric stroke

A.09.1 Thromboembolic events

A.09.2 IntracraniaL

haemorrhage/bLeedingA.09.3 CerebraLvenous sinus

thrombosis

A.09.4 Dissedion (cerebrovascular)A.0(;).5 Arteriovenous

malformations

A.10 Battered child

A.11 Coma

A.12 Brain death

A.13 Intoxications

B NeonatologyB.C)1 NeonataL seizures

B.02 NeonataL hypoxic-ischaemicencephalopathy (HIE)

E Epilepsy

E.01 EpilepsyE.02 First seizure

E.03 ParoxysomaLevent»(non-epileptic)E.04 West-SyndromeE.05 Benign epilepsy with

centrotemporaL spikes (BECTS,RoLandic epitepsy)

E.06 Absence epilepsyE.07 JuveniLe myoclonic epiLepsyE.08 LocaLizing signs in epilepsyE.09 Therapeutic strategies in

different electroclinicaL epiLepsysyndromes

E.10 EpiLepsy surgery

F Vertigo

F.01 Vertigo and dizziness

G Movement disorders

G.01 CerebraL palsyG.02 Dystonia

H Cranial nerves

H.01 FaciaL patsyH.02 0ptic neuritis

I RehabiLitation

I.01 Rehabilitation (inpatient)

N Neurometabolic and

neurodegenerative disorders

N.01 NeurometaboLic disorders

N.02 Neurodegenerative disordersN.03 Mitochondrial disorders

0 Neuromuscular disorders

0.01 Neuromuscular disorders

0.02 Muscle dystrophies0.02.I Duchenne-Becker

muscular dystrophy(DMD, BMD)

0.02.2 Limb-girdle musculardystrophy ( LGM D)

0.02.3 Emery-Dreifuss Syndrome0.02.4 Myotonicdystrophy,

Dystrophia myotonica (DM)0.02.5 Facio-scapuLo-humeraL

muscular dystrophy (FSHD)0.02.6 DistalmuscuLardystrophy0.02.7 Congenital muscular

dystrophy (CMD)0.03 Myopathies0.04 Myositis0.05 SpinaL muscu(ar atrophy (SMA)0.06 NeuromuscuLartransmission

0.07 Peripheral nerve lesions0.08 Neuropathies

C Pain

C.O'l Headache

C.02 Primary HeadacheC.03 Secondary HeadacheC.04 Pain managementin paLLiative careC.05 Idiopathic intracraniaL

hypertension (IIH)

D Development

D.C)I Deve(opmentaL disordersD.02 Hyperkinetic disorderD.03 Education entrance qualification

(schooL maturity)D.04 Tic disorder and Tourette

syndromeD.05 Autism spectrum disorder (ASD)D.06 FetaLaLcoholspectrum disorders

(FASD)

J Inflammation and infection

J.01 MuLtipLe sclerosis/ADEMJ.02 CerebralvascuLitis

J.03 Lyme diseaseJ.04 Meningitis and encephalitis

K Oncology

K.01 Neoplasm ofthe CNS

L Genetics

L.01 Genetics

L.02 Neurocutaneous syndromesL.03 CraniosynostosisL.04 RettsyndromeL.05 Microdetetion syndromesL.06 Trisomy 21

M Autonomic nerve system

M.01 HypersaLivation and dysphagiaM.02 BLadder dysfunctionM.03 Sleep disorders

P Hydrocephalus, Myelomeningocele(MMC), Chiari Malformations

P.01 Hydrocephalus in infantsP.02 Management ofthe shunted

hydrocephaLusP.03 Myelomeningocele (MMC)P.04 Chiari maLformations (CM)

Q Neuro-Orthopaedics

Q.01 HipjointQ.02 ScoLiosis

R Neurological examinations

Medication

4/11

mNeuro,.dC:-)1d iPad Screenshots NeuroKids

mNeuroNls

it.iWKoh'ha""a'

iPad 9 16:09 '?Lädtnich}?')

IIEGet Access

Preface

How to use this app

Abbreviation

List of Authors

Support Groups

Notifications

Feedback

Cooperation Partners

Imprint

r NeuroKids

C' Emergency and intensive care

Neonatology and perinatolügy

la Pain

Developmental neurology and psychiatry

&

II

1

NeuroKidsl

j

11

j

"lr.

Kohlhammerl?

iPad 9 lSupport Groups

Get ACCe'iS

Preface

HOW to use this app

Abbreviation

List of Authors

Support Groups

Notifications

Feedback

Cooperation Partners

Imprint

r NeuroKids

l Q

Emergency and intensive care

:' Neonatology and perinatülogy

Pain

Developmental neurology and psychiatry

1l1I

i

r' i i ir+f' roups'%l l l UlA p p Ilj l

A: Emergency and intensive care

A.01 Febrile seizure, see chapter E

A.02 Status epilepticus (SE), see chapter E

A.03 Acute dystonic reaction, see chapter G.02

A.04 Acute Ataxia:

Ataxia UK

Lincoln House

Kcnninqton Park1-3 Brix}on RoadLündon. SW9 6DE

Great Bri!ain

Phüne: +44-'20 7!i89 1444

Fax: +44-20 7582 9444

Homepage: www.ataxia.org.uk >

A.05 Acute increased intracranial pressure (ICP), see chapter P jA.06 Guillain-Barre syndrome (GBS):

nP": IrlnP Fril indaliOn In{erna{ional

The Holly Building - 104 142 Fotrest Avenuel'irbprth, PA. tqnzz

uSAT?snone: + 610-667-0131

Fax: +1-fün-667-7036

Home(»aqe: wwvii.qbs-cidp.orq >

r.Al>I? ri iilhin-F!attti & A'ssori lmaföry %eli7pri.Jliie6

5/11

iM

iPad Screenshots NeuroKids

l iPad ?

<

?A.01 Febrile seizures

Q

. ....'. Diagnosis

. .."' Therapy

is:og

A.01 Febrile seizures

Diagnosis

""]-; r

»yalaal

?0;+..i..-. Css[bXlib?uilvwl

C?

r?*bmea:ia?l

lag*&almall-a--?li??

?Lädtnich(?)

[03

-41%-€-14

OIM 4%%I!

Iw«0lW*OWaiml

l DiagnOSiS Therapy i

6/11

mma

s2W

iPad9 16109 Lädtmch}i

NeuroKids = JL]e

Emergency and intensive care

l

Neonatology and perinatology

"@@Pain

Developmental neurology and psychiatry

Epilepsy

Vertigo

Movement disorders

#Cranial nerves disorders

Rehabilitation

Inflammation and infectious diseases of

' the central nervous system -

Oncology "" '

Genetics

&Disorderoftheautonomic nervesystem @ ,: Neurometabolic and neurodegenerative

disorders

T. nxn2,k

Imm0

QJ

NeuroKids

»-fi/d iPhone Screenshots

mNeuro,,.1s

NeuroKids N

ffl 'lGet Access

Pre1ace

How to use this app

45576viation

l ist of Authors

Support Groups

Notifications

Feedback

roopsration Partners

Imprint

F€

r4.0j pB5(%le seizures ]

$1

lDiagnosis

Thetapy

r @@@@@ Tele)om.de 9

(Back

16:02 lla:)(

3

Support Groups

A: Emerqency and intensivecare

A 01 Fpbrilp qpi'iure, see chapter E

A.02 Status epilepticus ISE), seechapter E

A O! Acute dystonic reaction, seechapter G.02

A 04 Acute Ataxia:

Aiaxia UK

Lincoln Housem?Kenning}on Patk

1-3 Brixfön Road

l ondon oWa c

Greai Bri(ain

Phone: +44-20 7582 1444r- {I aa'yrnav'?x 4

Homepage: ICli u >

A 05 Acute iricreased intracranial

pressure I?CP? epp rhaptpr P

rlll

l

iri

r

Ü. I61fü

(BackA.01 Febrile seizures

Diagnosis

?..«?w*#

%?(

I??

'1.»"';l

s

8/11

*****Telekom.de"' 16:02 (Wll

( A Emergency and intensive care ffi

I -=-=-=-l -=-=-=-=-

Acute iiicreased intyacranial

' " pressure(ICP)

.. .' Guillain-Barrö Syndrome (GBS)

l -------=-=-=-=-l =-=-=-------=l =-=---------

*.sx ':.v

00000 Telekom.de 1 18:02 'T {-k

A.01 Febrile seizures<3ack Thetapy 'E.

x

(.on}inuing seizute:

k Midazolam @ IV 0;l-0.2 mg7kg/single dose

O(

k Lorazepam @ IV O,C6-0,1 mg}kg/single dose

or

> Cnazepam @ 0,25 mg7kg/single dose

In case o} continuing SelZu(e:

s Phenoba+biLal @ IV 10 mg/kg/single dose

hhs*sTelekom.de a I8:02 4 '-]D+

A.01 Febrile seizures<BaCk üiagnOSlS Y

......,..,....=...,....,,.,.,.,.1testing; ij negative: SCN9A and PCDH19)

mNeuro,Idc

J Workbook sample pages

Medication

A

Acelazolamide IAZAI

DoaaHe:

» rpiltpxy:8-}Omgjkgld(axxtattdintheSummxryo[Pyodu«tChyat«ei!xikx.SPCl» «ype 2 epixt»dlt a«ixxix: 5-10 mglkgJd ko[[-föbxllb :d!opathic imrxcyanixl hyptvitnsksnlpxtudoiumoy cvrtbvi {o[[-Ixbtll

- !n{xmi: initixl doxt 8 mgJkgJd tt 3 xxpux«r doi?ey. intvtaxe il yequ!red lo amaximum o{ 100 mgJkgldthiklven: xtxvi iviih .)5 mgJk(}d, in«yxair by 25 mglkpJd il ttqu!ytd(max. 100 iiig}kg{d ov ! Jd)

? adolexctiiis: xiayt with 25 mg%yJd. in«yeaye by )5 mg+kzld i[ trquitxd(max. 100 mglkgM ö} 2 g{d)

b «rnml yrxpiyatory dixoydxr wiih attompxnying hl'poxxm!a: 7.5-lü.0mJkg{dItau«!on: mr«abol!t dvtompenyx«!onl

Nvumpavd!a«vlc iiidiciitioiit:

yvduttion ot tryebyoipinal nuid ICSP) pyodut«ioii rritli iiitrtxx« ol !n«ta«yxnialpyxxxuyt (ICP) (intmdiiig poxilirmt?yyhxgi« vxn«y!tulxy d!Ix«ütion and idlopx{h!«:niyatnnW liyptt«eny:onlaltrynziive thrtapy [ot pmlal. genxyaliud oy slixvntt epiltpq {ihoit?irtm)

- typr 2 tp!xod!c a{xxix? «tnu?xl ttipitato«?y dixoydey wilh ati:ompxiiyinB hypoxrmia

Mechan!ym ol acr!on:

- «aybonic anhydyxxe iiihibilor

Relevank wiirva!iid!xak!onx:

? hypokxlvm!a. hypona{yemix

Re{evaiix y!de elleay hnd !mevacr!anx:

mvlxbolik iv:idoy!s

1»?vqueiil uiiiiülioiitkin raxh

payry{hvxixliypvy«xltiuvixlnxphmlithixxii

?- nvphmtox!t in tomb!nn{!on wi{Is NSAIDi-:n«iiixye ö( Csybamxzvp!iit Ixvrl

Inyvly) Sixvvny4olmxon iyndtomr

*ppniml swui: -

Souicvy:

G*rmxsy - IPC: -U%A - Tl

- *puvpx'rxnl

l- 10 mH%ld u l-i xqyyyi* dag*a. #01 is «x*d )n mlJld ny l dl: tmn)tl wlxut oygffl* 10 001«*asxx*sl*d (O( u*gm*n« ni *yX«yii

«]ss*

- oTh 0( IV

?. isH%ldagalDn«likmdmahluyXDus:l*d K!aHd*x - BNO{?:

- *yN*pay

- 04ffl 01 h} Ob# 1011{Ok%0%X i%lKliNk

?. s**sai*: ixi«W )ny« !3 m(% !-) iimtx ]y:li: mglm*ass* dosv }J mHlky }-I iimn ]yXi? ahlldza l mnülh-I} y«yy: Ixl«id du* 1.1 sHlkH l-] «lmvg nxili. lö%nia«d }} }-l m)IJ

)-l üm«x J01ly. m+x. 150 mHld {mxuu*xgxb dnxl. ahllAr*x ?l-111 }00I0: !}0 111! !-l lim*x (hi!i

? xbal Ixi*a*sW pr«zz*yv- saal 00 Ly alss ini+mxniiy ixjt«iinn

- ahlkla*n l monlh-I} l'vxry: ixlW Jl)I} 0 *H% i 1:00(0 flally. Ix«inxisH yx xv«vxxyq in föL}.l(X my%ld

Commim:

? «xix[ul uyv o[ loiig tanii xdmiiiixmtion? [yrqurni «on«tol o[ x«!d-füxt homroxtsiix äl wrll !I rlxayt?lyivs

Acetylsalicylic acid iASA)

Dosage:

» y«yokr prophylaxiy: l-) mgJkyJdiiiitial doxv [ot x«u«x x«yokr matmrnt ay iii xut of ttmpnvxq xymptomx:3-5 mglkgld liiitoi'i+ialion only [oy xdul!y xva!lable. +iüt [oy fhildyenl

? x{itv 3-6 mo+ilht üt LMWH «rrmpy [olliiwiiig thi tliiiitally acutt phxx+. in iixixblt tinnatioii: )-5 mglkgld Ino mföi'mttion on doxxgt xiid tolziföi!ity or ASAavxilablt lot iitwbotiis)

b acuie ttnx:on-typr htxaatiie Ire!Imenll 10-15 mg}kg p.o.rw» a«ute migiaine tytütmtm: 10-15 mgAg p.o.+Wb m!gnine pyophylxxix: 2-3 mgJk(}d p.o.b Kawxxaki ilixeaxt with [evrv: }O mgJk0d ov Hü-100 mlkgM üs 4 xtpiüalt doxrx

OVky 48-72 11. WlöWkd liy 3-} mdkdd: diXkön{!niie {Ik!{men{ ni{el 6-8 WkkkX

A

39I

Nxurophed!akv!x !ndlcm{!ony:

?- py:msiy snd xrtondxi?y x«yokr pyxveii«!onlpvophylnxixt«niion-typ« lirnds«hräCull mig[&ine I}lflmlnl

? migyaine piophylaxiy-Kxwxnkl diiexxe

Michanitm ol nc«ion:

-inhibition o[pls«elrt üggiigütion föiough iiiliföitioii o( tyclo-üxygenxyr with «onxr-cu{!v« txdu«{!on oi {litomboxxne A2 üiid piiiitacltlin iy'rahexii

Relevant comya!nd!cak!ony:

ievryx livrt oy yrnxl [xiluye

«hildyrn and xdolrxcrnrx w!{h ixvvr!xh illiitxy

Relevünl x!de ellecky and !nlevacklonx:

-vxyy T!Il al low doxv? nauxn, lieay{buyn. vomiling

b»?t?ncho«onxtyn:t!on

mu«oial iriitatioii. y,axtyoimeyunsl lileiding and prpi!t ul«rryelxpxe oi Ichyon!t) !nnammstovy bowrl dixxxyxyRrye xyiidyomt iii «h!?dven (tnd xdoltittmi} wilh l'xvrviyh illnryx {liix{oy!«xl)

Appioval skakuy:

varirs dipending on pyodu«l (100 SPC)

Souvces:

Gsrmyny - SPC:

FIlJll{I[mI==-=-

Tkr !D yyx I»« Hlg*s *g*q ?l-% k. if a*a*saq.Uu - T:

- v.isyxx{l J!wxw

- nrffl

- 00-l W rx%lkdd nm)sl :010 ?l d04s. l.(. }N=} %Wlt. N]mWXlll[] }OOIY ! } iöl 00 In l ?l d {%nl!I@?[I 4[Xölvk! iö4 01 10041 nt h}: IL40 k44044 Th0 !W 10 )-} m%lJhl N%kk d[lly. fö [!li[OV401(xö%{ kk4kk0ff On0ff OLsa%.d:{140. 00011000 4011% Th} lö40 ]öK {01 k-[ #}}}}. fö [%{1001{ !Kilhtn«nsyq ggi*q gLa*?fflii:*a. wffabia Il+ las.]nyy Ir«ykmtm isdthi«yly liü yddllios In ILv«gyy-(:fö Wsrla«la}.

%l- iahki. :.(. +I0 mHW11-) IOLl0u. i.a. }Ok-110 In%

llll

yaxlH**la-. aTh, r*alsl. IV

- 10-I} *H% *?q l -t h. %%. ÄO%l l %Mynl:?:slbssx*lsq- s«ffl

- :s:»Wli: !k-% xylkHld flia:d*d 101(l +g««ffl )vy«x

. 4140ffl #0:%{Oaa%00 d04# [0-I» %%l[%ld %i0kk i0 [[[lOHvlN )kTOl NOkq k-% 11- **aiis« -{XA g*41'0% ?I%44n%%%0

- y»{lyW*W *fi*au

g)sl*g«* pg*fl:ania g«*d:*a hga* 001 'x*s ?+«lam*d: yy*]iy!ylv dnxyy* ix )*«ia*d lynm ad«]l g{*dlag00} d:a:*l *ap*ri*aa* asl ü #01 »a*% *g«a}Ilgl?

- %H*gid dag*g hga* «gaypd }0## l-i sylkHld io I-10 mHfl-yl { yx t XD. D«*y y< l) plo%i g**sd*]

- ?04!Ol !%hss!0 01(0100, 400%#0%ll l i ?I{dl N[ f XD [llkl !Nlikö[{vl[llk% I}[40Ji Is4 Is00):s*i»i:a**).

Um!? KlsH]aw - &Nr'C:- KxwxsxlU IIM?K

? 0föl

xvnxy{vx: ixliUy 11 mHl{vll u ?l xtym«g«* J***a is« ) »a**l.a 0( 001:l aivLill«. {olhasvl }} } ixy%ld {T ! XD hsi k-[ s«kx: il iin w:d««* ni as«saaq I*a:*aa gl{*« [ s+la. ]ia«nxiixv« u*y«myxi nrx««y *?i« y(Ivkt«hll)r*n l movah- 11 yexu: :alb%y }0-1% *y%ld ag l #yaT010 hlly n««x lög l «a*«{x 01 vi»iilyl*L«ll«. fö0N !-I mlkHld sg a (D im k-x »a**ü :+ i»* *a:]**av *{anrnnx'- I*xlanx yl«ty [ #0*k!.nix«oxiinvy «inim*xt or x«k *xy*n gda:a*

? Inblbllfön ö( plyl? ygpvHxi!ns. yha*si!ss s[ Th«s*{ga L*«m*ilsn *ll«y «ydü« xvvHvq- oad

- x«nyl«x:l-laaH%l)axglD- «hlldy*n l mnsTh- l) l*m: l-i mH%)d Isg*ffl isax. :I m0 01 t (D- ahlMbü I}-va ybgy: )l sHld 11( a ID

IV «ommen{:

? incyessxd (potent!allylh!ytoyicxll i?itk ol dvvxlopiiig RIYI yyiidromt (< 12 ymy)yhould not bi xdminiiteyxd diiting xcu«e Lrliyile d!yexyt (vxpeaally vayittlla dii«urxnd :nlluinza)

- üpiiontl monito+ing ol xmi«ox@ulx«ion: plxreltt {un«tion ittiing

A

392

10/11

INmmmm

mElmmg